These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8562586)

  • 1. GI distress: clues in the patient's medications.
    Everette SS
    Gastroenterol Nurs; 1995; 18(6):219-23. PubMed ID: 8562586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.
    Thomas J; Straus WL; Bloom BS
    Am J Gastroenterol; 2002 Sep; 97(9):2215-9. PubMed ID: 12358235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal antiinflammatory drugs. A review.
    Winzeler S; Rosenstein BD
    AAOHN J; 1998 May; 46(5):253-9; quiz 260-1. PubMed ID: 9652239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
    Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
    Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiplatelet effects of aspirin and related component drugs on the surgical patient.
    Kelsey M
    J Post Anesth Nurs; 1993 Apr; 8(2):101-3. PubMed ID: 8501653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
    Zandman-Goddard G; Langevitz P
    Harefuah; 2001 Jun; 140(6):476-8, 567, 566. PubMed ID: 11420844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
    Lanas A; Scheiman J
    Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
    Harris CL; Raisch DW; Abhyankar U; Marfatia S; Campbell HM; Sather MR
    Ann Pharmacother; 2006 Nov; 40(11):1924-31. PubMed ID: 17047140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of NSAID complications: gastrointestinal and more.
    Beehrle DM; Evans D
    Lippincotts Prim Care Pract; 1999; 3(3):305-15. PubMed ID: 10711132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awareness and frequency of potential side effects on nonsteroidal anti-inflammatory drugs among the Jordanian patient population.
    Albsoul-Younes AM; Jabateh SK; Abdel-Hafiz SM; Al-Safi SA
    Saudi Med J; 2004 Jul; 25(7):907-11. PubMed ID: 15235698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
    Cryer B; Miller P; Petruschke RA; Chen E; Geba GP; Papp AE
    Aliment Pharmacol Ther; 2005 Mar; 21(5):599-607. PubMed ID: 15740544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain.
    Steiner TJ; Voelker M
    J Clin Pharm Ther; 2009 Apr; 34(2):177-86. PubMed ID: 19250138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
    Lanas A; Hunt R
    Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
    Fries JF; Bruce B
    J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.